MATINAS BIOPHARMA HOLDINGS, INC. Available-for-sale Securities, Gross Unrealized Loss
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Available-for-sale Securities, Gross Unrealized Loss of $10.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2021-08-10
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2021-06-30 was $8.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2021-03-31 was $2.00K, a 22122.22% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2020-09-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2020-06-30 was -$8.00.
- MATINAS BIOPHARMA HOLDINGS, INC. available-for-sale securities, gross unrealized loss for fiscal 2019 was $2.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2021-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $10.00K 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | $2.00K 10-Q · filed 2021-05-10 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$8.00 derived: sum of 2 quarters · filed 2020-11-06 | $1.00 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$8.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.00 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $9.00 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $2.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |